Biotech - Spark Newswire

5 minute read

Alnylam Presents Additional Results From The APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy At Heart Failure Society Of America Annual Meeting

Yesterday, 2:03 PM

– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging,

ALNY

1 minute read

FDA Says Livanova Recalls Lifesparc System For Risk Of Unintentional Extended Pump Stop During Controller Critical Failure

By Benzinga Newsdesk

Yesterday, 10:49 AM

- Reuters

LIVN

1 minute read

Aileron Therapeutics Announces Oral Presentation Of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles And Their Stem Cells From Chemotherapy-Induced Damage At The European Society For Dermatological Research Annual Meeting 2022

By Benzinga Newsdesk

Yesterday, 8:43 AM

New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May

ALRN

2 minute read

Edesa Biotech Reports Statistically Significant Mortality Reductions In Phase 2 ARDS Drug Study; Says ‘EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo’

By Benzinga Newsdesk

Yesterday, 8:02 AM

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Report

EDSA

2 minute read

Ainos Announces Results From Additional Preclinical Study Of Its Low-Dose Oral Interferon Formulation; Showed ‘showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period…

By Benzinga Newsdesk

Yesterday, 7:04 AM

VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period. By upregulation of immunomodulatory, Ainos'

AIMD

1 minute read

Zealand Pharma Announces Results From Phase 3 Trial Of Glepaglutide; Glepaglutide Treatment Met Primary Endpoint

By Benzinga Newsdesk

Yesterday, 6:17 AM

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a

ZEAL

6 minute read

Rocket Pharmaceuticals Announces Updates From Phase 1 Clinical Trial For RP-A501

By Benzinga Newsdesk

Yesterday, 6:03 AM

— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein

RCKT

1 minute read

FDA
News

Amylyx Pharmaceuticals Receives FDA Approval Of Relyvrio For Treatment Of Amyotrophic Lateral Sclerosis

By Michael Horton

September 29, 4:38 PM

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216660

AMLX

3 minute read

Iridex Showcases Its Non-Incisional Treatments For Glaucoma, Introduces Sweep Management Software, And Hosts 8 Physician Presentations At AAO 2022

By Benzinga Newsdesk

September 29, 4:08 PM

MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to

IRIX

1 minute read

Immunovant’s New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

By Vandana Singh

September 29, 2:36 PM

On Wednesday, Immunovant Inc (NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd’s (NASDAQ:ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody…

ARGX